Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
about
Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis--an observational cohort study.Epidemiological aspects of genital warts in romania - a 2012 retrospective surveyA novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in miceTargeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.[Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis].Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines.Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10.Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.Viral infections and human cancers: the legacy of Denis Burkitt.Multiple infections and cancer: implications in epidemiology.The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review.Phospholipid supplementation can attenuate vaccine-induced depressive-like behavior in mice.Intracervical procedures and the risk of subsequent very preterm birth: a case-control study.[Researcher of the month, October 2012].
P2860
Q34802753-F376C5CD-95C6-457C-83FB-48602B01FFB9Q34976874-C3F4EDB1-BC40-42C3-A597-173BA5062E0CQ35009410-D41C01DF-A967-4A3A-AF0A-69000118BE32Q35274806-ED0B3484-40FE-49AA-8C97-15DA7C256F47Q35427518-0AD82DA1-3E68-4D6B-962A-975248AF7DDAQ36916512-C34752D3-424A-4185-940A-6B0C449010B2Q37514776-BC58C067-CC83-40F1-A3D2-F5D3EB26955DQ37587225-E3DEC48E-1D52-41D4-AB87-6D594EFD49FFQ37937705-D0B5C676-7376-4AD5-AA1B-CE98F2C68D98Q37974711-601249E6-61F1-4C2E-827D-9E663D7BFA0DQ38126931-0D1CE257-04B6-4C4E-9716-5E82AA48AE12Q39450074-D46BE97F-CD47-4539-BF90-43159F1003ABQ40597501-057CEB51-CDD5-4197-B641-D276EE3D64B6Q45000450-E11258A1-E73C-4527-9507-DAB8F96373E3Q52340945-4DF57110-EE80-4CBD-88D2-7E5E60B1EA43
P2860
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quadrivalent human papillomavi ...... er and genital warts in women.
@en
Quadrivalent human papillomavi ...... er and genital warts in women.
@nl
type
label
Quadrivalent human papillomavi ...... er and genital warts in women.
@en
Quadrivalent human papillomavi ...... er and genital warts in women.
@nl
prefLabel
Quadrivalent human papillomavi ...... er and genital warts in women.
@en
Quadrivalent human papillomavi ...... er and genital warts in women.
@nl
P2860
P1433
P1476
Quadrivalent human papillomavi ...... er and genital warts in women.
@en
P2093
Elmar A Joura
Paul L McCormack
P2860
P304
P356
10.2165/11204920-000000000-00000
P577
2010-12-01T00:00:00Z
P5875
P6179
1032224017